NR3C1 and breast carcinoma: In hormone receptor-positive (ER+) breast cancer, Dex maintains TLS functional integrity through multiple synergistic mechanisms (37):At the transcriptional level, Dex suppresses the NF-κB signaling pathway via glucocorticoid receptor (GR)-mediated genomic effects, reducing the expression of key pro-inflammatory cytokines IL-6 and TNF-α by approximately 60% in the TLS-surrounding stroma, thereby mitigating chronic inflammation-induced structural damage.